|Mr. Tilmann Bur||Member of Exec. Board||257k||N/A||1966|
|Mr. Matthias Meissner||Director of Corp. Communications & Investor Relations / PR||N/A||N/A||N/A|
co.don AG, a biopharmaceutical company, develops, produces, and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. It offers Spherox, a three dimensional chondrocyte product that is used to treat cartilage defects in adult knee joints; and co.don chondrosphere for the treatment of cartilage defects in the hip, ankle, shoulder and elbow, and knees of younger patients. The company serves accident and orthopedic surgeons. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.
co.don AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.